{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:24:33Z","timestamp":1794000273506,"version":"4.8.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Elsbeth Bonhoff Stiftung","award":["228"],"award-info":[{"award-number":["228"]}]},{"name":"Elsbeth Bonhoff Stiftung","award":["228"],"award-info":[{"award-number":["228"]}]},{"name":"Elsbeth Bonhoff Stiftung","award":["228"],"award-info":[{"award-number":["228"]}]},{"name":"Elsbeth Bonhoff Stiftung","award":["228"],"award-info":[{"award-number":["228"]}]},{"name":"Elsbeth Bonhoff Stiftung","award":["228"],"award-info":[{"award-number":["228"]}]},{"name":"Elsbeth Bonhoff Stiftung","award":["228"],"award-info":[{"award-number":["228"]}]},{"name":"Abbvie, Amgen, Almirall, Biogen, BMS, Chugai, Galapagos, Generic Assays, GSK, Hexal, Horizon Therapeutics, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche and Sanofi"},{"DOI":"10.13039\/100001275","name":"The Oak Foundation","doi-asserted-by":"crossref","award":["OCAY-18-774-OFIL"],"award-info":[{"award-number":["OCAY-18-774-OFIL"]}],"id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001275","name":"The Oak Foundation","doi-asserted-by":"crossref","award":["OCAY-18-774-OFIL"],"award-info":[{"award-number":["OCAY-18-774-OFIL"]}],"id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001275","name":"The Oak Foundation","doi-asserted-by":"crossref","award":["OCAY-18-774-OFIL"],"award-info":[{"award-number":["OCAY-18-774-OFIL"]}],"id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001275","name":"The Oak Foundation","doi-asserted-by":"crossref","award":["OCAY-18-774-OFIL"],"award-info":[{"award-number":["OCAY-18-774-OFIL"]}],"id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>It is unclear whether sex or age modify the association of glucocorticoid (GC) use with reduced bone mineral density (BMD) in patients with rheumatoid arthritis (RA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We studied cross-sectional data of RA patients with current or previous GC treatment in a single center cohort study (<jats:italic>Rh-GIOP<\/jats:italic> cohort). Our primary outcome was the minimum T-score (measured by DXA) of either lumbar spine, total femur, or femoral neck. Current GC dose was the main exposure; cumulative GC dose and cumulative duration of GC use were also assessed. Following a predefined statistical analysis plan, linear regression analyses with adjustment for confounders assessed whether the association of GC use with BMD was modified by sex (men versus women) or age (\u2265\u200965 versus\u2009&lt;\u200965\u00a0years).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Four hundred eighty-three patients with RA (mean age 64\u2009\u00b1\u200912\u00a0years, 80% women) were included. 33% were not currently taking GCs, 32% were treated with a dose of 5\u00a0mg\/d prednisone equivalent and 11% with more than 7.5\u00a0mg\/d. 23% of patients had osteoporosis by DXA (minimum T-score\u2009\u2264\u2009-2.5). The slope, i.e., the association between changes in minimum T-scores with 1\u00a0mg\/d change in current GC dose, was similar in men and women (-0.07 and -0.04, respectively; difference -0.03 [-0.11 to 0.04]; <jats:italic>p<\/jats:italic> for interaction\u2009=\u20090.41). Slopes were also similar for elderly and non-elderly patients (-0.03 and -0.04, respectively; difference -0.01 [-0.06 to 0.05]; <jats:italic>p<\/jats:italic> for interaction\u2009=\u20090.77). Using cumulative dose and duration of use as exposures did not lead to substantial changes of these results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In our sample, the association of GC use with reduced BMD in RA was not modified by sex or age.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03083-x","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T06:01:48Z","timestamp":1686117708000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sex and age do not modify the association between glucocorticoids and bone mineral density in patients with rheumatoid arthritis: a cross-sectional study"],"prefix":"10.1186","volume":"25","author":[{"given":"Andriko","family":"Palmowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhivana","family":"Boyadzhieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina M.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Muche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Boers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Bliddal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Wiebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"issue":"2","key":"3083_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","volume":"44","author":"F Matcham","year":"2014","unstructured":"Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(2):123\u201330. https:\/\/doi.org\/10.1016\/j.semarthrit.2014.05.001.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"3083_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.berh.2011.10.009","volume":"25","author":"NJ Gullick","year":"2011","unstructured":"Gullick NJ, Scott DL. Co-morbidities in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2011;25(4):469\u201383. https:\/\/doi.org\/10.1016\/j.berh.2011.10.009.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"3083_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00393-015-0019-5","volume":"75","author":"K Albrecht","year":"2016","unstructured":"Albrecht K, Callhoff J, Edelmann E, et al. Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA. Z Rheumatol. 2016;75(1):90\u20136. https:\/\/doi.org\/10.1007\/s00393-015-0019-5. [published Online First: 2015\/12\/19].","journal-title":"Z Rheumatol"},{"issue":"11","key":"3083_CR4","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1136\/annrheumdis-2016-210135","volume":"76","author":"C Roubille","year":"2017","unstructured":"Roubille C, Rincheval N, Dougados M, et al. Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort. Ann Rheum Dis. 2017;76(11):1797\u2013802. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210135. [publishedOnlineFirst:2017\/02\/19].","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3083_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1136\/annrheumdis-2021-220112","volume":"80","author":"W Xie","year":"2021","unstructured":"Xie W, Huang H, Li G, et al. Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020. Ann Rheum Dis. 2021;80(8):997\u20131003. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220112. [publishedOnlineFirst:20210402].","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3083_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13075-017-1461-3","volume":"19","author":"RJ Black","year":"2017","unstructured":"Black RJ, Lester S, Buchbinder R, et al. Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry. Arthritis Res Ther. 2017;19(1):253. https:\/\/doi.org\/10.1186\/s13075-017-1461-3. [publishedOnlineFirst:20171115].","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3083_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/acr2.11334","volume":"4","author":"KM Andersen","year":"2022","unstructured":"Andersen KM, Schieir O, Valois M-F, et al. A bridge too far? Real-world practice patterns of early glucocorticoid use in the Canadian Early Arthritis Cohort. ACR Open Rheumatol. 2022;4(1):57\u201364. https:\/\/doi.org\/10.1002\/acr2.11334.","journal-title":"ACR Open Rheumatol"},{"issue":"26","key":"3083_CR8","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1056\/NEJMcp1800214","volume":"379","author":"L Buckley","year":"2018","unstructured":"Buckley L, Humphrey MB. Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2018;379(26):2547\u201356. https:\/\/doi.org\/10.1056\/NEJMcp1800214. [publishedOnlineFirst:2018\/12\/27].","journal-title":"N Engl J Med"},{"issue":"3","key":"3083_CR9","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1530\/eje-15-0118","volume":"173","author":"F Mirza","year":"2015","unstructured":"Mirza F, Canalis E. Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015;173(3):R131\u201351. https:\/\/doi.org\/10.1530\/eje-15-0118. [publishedOnlineFirst:2015\/05\/15].","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"3083_CR10","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/ard.61.8.718","volume":"61","author":"F Buttgereit","year":"2002","unstructured":"Buttgereit F, Da Silva JAP, Boers M, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61(8):718\u201322. https:\/\/doi.org\/10.1136\/ard.61.8.718.","journal-title":"Ann Rheum Dis"},{"key":"3083_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222339","author":"E Wiebe","year":"2022","unstructured":"Wiebe E, Huscher D, Schaumburg D, et al. Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222339. [publishedOnlineFirst:20220609].","journal-title":"Ann Rheum Dis"},{"issue":"7624","key":"3083_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806\u20138. https:\/\/doi.org\/10.1136\/bmj.39335.541782.AD. [publishedOnlineFirst:2007\/10\/20].","journal-title":"BMJ"},{"key":"3083_CR13","unstructured":"Dachverband Osteologie (DVO). Prophylaxe, Diagnostik und Therapie der Osteoporose. 2017. https:\/\/dv-osteologie.org\/osteoporose-leitlinien. Accessed 19 Apr 2022."},{"issue":"3","key":"3083_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw. 2011;45(3):1\u201367. https:\/\/doi.org\/10.18637\/jss.v045.i03.","journal-title":"J Stat Softw"},{"key":"3083_CR15","unstructured":"Russell V. Lenth PB, Iago Gin\u00e9-V\u00e1zquez, Maxime Herve, Maarten Jung, Jonathon Love, Fernando Miguez, Hannes Riebl, Henrik Singmann. emmeans: Estimated Marginal Means, aka Least-Squares Means. 2022. https:\/\/cran.r-project.org\/web\/packages\/emmeans\/index.html. Accessed 16 Jan 2023."},{"issue":"23","key":"3083_CR16","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","volume":"372","author":"JL Jameson","year":"2015","unstructured":"Jameson JL, Longo DL. Precision medicine \u2014 personalized, problematic, and promising. N Engl J Med. 2015;372(23):2229\u201334. https:\/\/doi.org\/10.1056\/NEJMsb1503104.","journal-title":"N Engl J Med"},{"issue":"6","key":"3083_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/2040620715607416","volume":"6","author":"S Giri","year":"2015","unstructured":"Giri S, Pathak R, Martin MG, et al. Characteristics and survival of BCR\/ABL negative chronic myeloid leukemia: a retrospective analysis of the surveillance, epidemiology and end results database. Ther Adv Hematol. 2015;6(6):308\u201312. https:\/\/doi.org\/10.1177\/2040620715607416.","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"3083_CR18","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00296-016-3506-3","volume":"36","author":"E Martin-Mola","year":"2016","unstructured":"Martin-Mola E, Balsa A, Garc\u00eda-Vicuna R, et al. Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. Rheumatol Int. 2016;36(8):1043\u201363. https:\/\/doi.org\/10.1007\/s00296-016-3506-3.","journal-title":"Rheumatol Int"},{"issue":"6","key":"3083_CR19","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1136\/ard.2009.114579","volume":"69","author":"MC van der Goes","year":"2010","unstructured":"van der Goes MC, Jacobs JWG, Boers M, et al. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2010;69(6):1015\u201321. https:\/\/doi.org\/10.1136\/ard.2009.114579.","journal-title":"Ann Rheum Dis"},{"key":"3083_CR20","unstructured":"Rosen H, Saag K. Prevention and treatment of glucocorticoid-induced osteoporosis: UpToDate. 2022. https:\/\/www.uptodate.com\/contents\/prevention-and-treatment-of-glucocorticoid-induced-osteoporosis. Accessed 8 Feb 2023."},{"issue":"11","key":"3083_CR21","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1002\/art.11283","volume":"48","author":"TP Van Staa","year":"2003","unstructured":"Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48(11):3224\u20139. https:\/\/doi.org\/10.1002\/art.11283. [publishedOnlineFirst:2003\/11\/13].","journal-title":"Arthritis Rheum"},{"issue":"9","key":"3083_CR22","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/art.1780280905","volume":"28","author":"CL Deal","year":"1985","unstructured":"Deal CL, Meenan RF, Goldenberg DL, et al. The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration. Arthritis Rheum. 1985;28(9):987\u201394. https:\/\/doi.org\/10.1002\/art.1780280905.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"3083_CR23","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/1756-185X.12861","volume":"20","author":"TC Tan","year":"2017","unstructured":"Tan TC, Gao X, Thong BYH, et al. Comparison of elderly- and young-onset rheumatoid arthritis in an Asian cohort. Int J Rheum Dis. 2017;20(6):737\u201345. https:\/\/doi.org\/10.1111\/1756-185X.12861.","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"3083_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.archger.2005.07.003","volume":"42","author":"N Turkcapar","year":"2006","unstructured":"Turkcapar N, Demir O, Atli T, et al. Late onset rheumatoid arthritis: clinical and laboratory comparisons with younger onset patients. Arch Gerontol Geriatr. 2006;42(2):225\u201331. https:\/\/doi.org\/10.1016\/j.archger.2005.07.003.","journal-title":"Arch Gerontol Geriatr"},{"issue":"9","key":"3083_CR25","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/ard.2005.051144","volume":"65","author":"Z Tutuncu","year":"2006","unstructured":"Tutuncu Z, Reed G, Kremer J, et al. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006;65(9):1226\u20139. https:\/\/doi.org\/10.1136\/ard.2005.051144.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3083_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1741-7015-7-12","volume":"7","author":"RF van Vollenhoven","year":"2009","unstructured":"van Vollenhoven RF. Sex differences in rheumatoid arthritis: more than meets the eye. BMC Med. 2009;7(1):12. https:\/\/doi.org\/10.1186\/1741-7015-7-12.","journal-title":"BMC Med"},{"issue":"1","key":"3083_CR27","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1186\/ar2591","volume":"11","author":"T Sokka","year":"2009","unstructured":"Sokka T, Toloza S, Cutolo M, et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009;11(1):R7. https:\/\/doi.org\/10.1186\/ar2591 [publishedOnlineFirst:20090114].","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"3083_CR28","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.3390\/jcm9103361","volume":"9","author":"P Fardellone","year":"2020","unstructured":"Fardellone P, Salawati E, Le Monnier L, et al. Bone loss, osteoporosis, and fractures in patients with rheumatoid arthritis: a review. J Clin Med. 2020;9(10):3361.","journal-title":"J Clin Med"},{"issue":"3","key":"3083_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1447-0594.2006.00341.x","volume":"6","author":"H Orimo","year":"2006","unstructured":"Orimo H, Ito H, Suzuki T, et al. Reviewing the definition of \u201celderly.\u201d Geriatr Gerontol Int. 2006;6(3):149\u201358. https:\/\/doi.org\/10.1111\/j.1447-0594.2006.00341.x.","journal-title":"Geriatr Gerontol Int"},{"issue":"7","key":"3083_CR30","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/ggi.13118","volume":"17","author":"Y Ouchi","year":"2017","unstructured":"Ouchi Y, Rakugi H, Arai H, et al. Redefining the elderly as aged 75 years and older: proposal from the Joint Committee of Japan Gerontological Society and the Japan Geriatrics Society. Geriatr Gerontol Int. 2017;17(7):1045\u20137. https:\/\/doi.org\/10.1111\/ggi.13118.","journal-title":"Geriatr Gerontol Int"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03083-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03083-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03083-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T06:05:11Z","timestamp":1686117911000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03083-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3083"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03083-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"15 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Rh-GIOP cohort study has received a positive vote from the local ethics committee (EA1\/367\/14) and is registered with clinicaltrials.gov (NCT02719314). All participants had to give their written consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed for this manuscript to be sent for peer-review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AP, RC, SMN, SH, and ZB have no relevant conflicts of interest. EW reports consultancy fees, honoraria and travel expenses from Medac and Novartis. BM received consulting and speaker honoraria \/ congress support from UCB Pharma Germany, Amgen Germany, Stadapharm. FB reported receiving consultancy fees, honoraria and travel expenses from Abbvie, Horizon Therapeutics, and Pfizer, and grant support from Horizon Therapeutics. MB. consultancy fees from Novartis, speaker fees from Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}